112 related articles for article (PubMed ID: 30450632)
1. CTCs-derived xenograft development in a triple negative breast cancer case.
Pereira-Veiga T; Abreu M; Robledo D; Matias-Guiu X; Santacana M; Sánchez L; Cueva J; Palacios P; Abdulkader I; López-López R; Muinelo-Romay L; Costa C
Int J Cancer; 2019 May; 144(9):2254-2265. PubMed ID: 30450632
[TBL] [Abstract][Full Text] [Related]
2. The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling.
Vishnoi M; Liu NH; Yin W; Boral D; Scamardo A; Hong D; Marchetti D
Mol Oncol; 2019 Sep; 13(9):1913-1926. PubMed ID: 31216110
[TBL] [Abstract][Full Text] [Related]
3. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer.
Ramani VC; Lemaire CA; Triboulet M; Casey KM; Heirich K; Renier C; Vilches-Moure JG; Gupta R; Razmara AM; Zhang H; Sledge GW; Sollier E; Jeffrey SS
Breast Cancer Res; 2019 Aug; 21(1):98. PubMed ID: 31462307
[TBL] [Abstract][Full Text] [Related]
4. Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
Wu F; McCuaig RD; Sutton CR; Tan AHY; Jeelall Y; Bean EG; Dai J; Prasanna T; Batham J; Malik L; Yip D; Dahlstrom JE; Rao S
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31238530
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients.
Bittner AK; Keup C; Hoffmann O; Hauch S; Kimmig R; Kasimir-Bauer S
J Cell Mol Med; 2020 Aug; 24(15):8405-8416. PubMed ID: 32558176
[TBL] [Abstract][Full Text] [Related]
6. Tumor shedding and metastatic progression after tumor excision in patient-derived orthotopic xenograft models of triple-negative breast cancer.
Razmara AM; Sollier E; Kisirkoi GN; Baker SW; Bellon MB; McMillan A; Lemaire CA; Ramani VC; Jeffrey SS; Casey KM
Clin Exp Metastasis; 2020 Jun; 37(3):413-424. PubMed ID: 32335861
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells in non-metastatic triple-negative breast cancer.
Karhade M; Hall C; Mishra P; Anderson A; Kuerer H; Bedrosian I; Krishnamurthy S; Lucci A
Breast Cancer Res Treat; 2014 Sep; 147(2):325-33. PubMed ID: 25164970
[TBL] [Abstract][Full Text] [Related]
8. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
[TBL] [Abstract][Full Text] [Related]
9. NOTCH3 expression is linked to breast cancer seeding and distant metastasis.
Leontovich AA; Jalalirad M; Salisbury JL; Mills L; Haddox C; Schroeder M; Tuma A; Guicciardi ME; Zammataro L; Gambino MW; Amato A; Di Leonardo A; McCubrey J; Lange CA; Liu M; Haddad T; Goetz M; Boughey J; Sarkaria J; Wang L; Ingle JN; Galanis E; D'Assoro AB
Breast Cancer Res; 2018 Sep; 20(1):105. PubMed ID: 30180881
[TBL] [Abstract][Full Text] [Related]
10. Functional Analysis of Viable Circulating Tumor Cells from Triple-Negative Breast Cancer Patients Using TetherChip Technology.
Vardas V; Ju JA; Christopoulou A; Xagara A; Georgoulias V; Kotsakis A; Alix-Panabières C; Martin SS; Kallergi G
Cells; 2023 Jul; 12(15):. PubMed ID: 37566019
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
[TBL] [Abstract][Full Text] [Related]
12. Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy.
López-Ozuna VM; Hachim IY; Hachim MY; Lebrun JJ; Ali S
Sci Rep; 2016 Aug; 6():30934. PubMed ID: 27480353
[TBL] [Abstract][Full Text] [Related]
13. MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer.
Xu X; Zhang Y; Jasper J; Lykken E; Alexander PB; Markowitz GJ; McDonnell DP; Li QJ; Wang XF
Oncotarget; 2016 Apr; 7(15):20381-94. PubMed ID: 26967387
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
Madic J; Kiialainen A; Bidard FC; Birzele F; Ramey G; Leroy Q; Rio Frio T; Vaucher I; Raynal V; Bernard V; Lermine A; Clausen I; Giroud N; Schmucki R; Milder M; Horn C; Spleiss O; Lantz O; Stern MH; Pierga JY; Weisser M; Lebofsky R
Int J Cancer; 2015 May; 136(9):2158-65. PubMed ID: 25307450
[TBL] [Abstract][Full Text] [Related]
15. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells exhibit stem cell characteristics in an orthotopic mouse model of colorectal cancer.
Schölch S; García SA; Iwata N; Niemietz T; Betzler AM; Nanduri LK; Bork U; Kahlert C; Thepkaysone ML; Swiersy A; Büchler MW; Reissfelder C; Weitz J; Rahbari NN
Oncotarget; 2016 May; 7(19):27232-42. PubMed ID: 27029058
[TBL] [Abstract][Full Text] [Related]
17. Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
Song X; Zhou X; Qin Y; Yang J; Wang Y; Sun Z; Yu K; Zhang S; Liu S
Int J Mol Med; 2018 Jul; 42(1):579-588. PubMed ID: 29693154
[TBL] [Abstract][Full Text] [Related]
18. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
19. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions.
Saliou A; Bidard FC; Lantz O; Stern MH; Vincent-Salomon A; Proudhon C; Pierga JY
Expert Rev Mol Diagn; 2016; 16(1):39-50. PubMed ID: 26568208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
